类风湿关节炎相关间质性肺病免疫抑制治疗的真实世界多中心肺功能轨迹研究
线性样条混合效应模型显示,治疗12个月后FVC%预计值较未治疗潜在反应改善+3.90%(P≤.001,95%CI 1.95-5.84),DLCO%预计值改善+4.53%(P≤.001,95%CI 2.12-6.94)。UIP型与非UIP型及药物选择对肺功能轨迹无显著影响。
要点
- 免疫抑制治疗与RA-ILD患者FVC和DLCO轨迹改善相关。
- UIP型与非UIP型及药物选择对肺功能轨迹无显著影响。
- 需前瞻性随机试验验证上述发现。
核心结论
- 免疫抑制治疗与RA-ILD患者FVC和DLCO轨迹改善相关,需前瞻性随机试验验证。
研究设计与样本
- 采用线性样条混合效应模型(随机截距)分析治疗前后肺功能变化。
主要发现
- 三种药物联合分析显示,治疗12个月后FVC%预计值较未治疗潜在12个月反应改善+3.90%(P≤.001,95%CI 1.95-5.84)。
- DLCO%预计值在12个月时改善+4.53%(P≤.001,95%CI 2.12-6.94)。
- UIP型与非UIP型及免疫抑制药物选择对肺功能轨迹无显著影响。
临床怎么用
- 对于RA-ILD患者,可考虑使用霉酚酸酯、硫唑嘌呤或利妥昔单抗进行免疫抑制治疗以改善肺功能轨迹。
- UIP型与非UIP型患者均可从免疫抑制治疗中获益,药物选择对肺功能轨迹无显著影响。
局限性
- 回顾性研究设计,缺乏随机对照,可能存在混杂偏倚。
- 需前瞻性随机试验验证 findings。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rheumatoid arthritis (RA)-associated interstitial lung disease (ILD) is common in patients with RA and leads to significant morbidity and mortality. No randomized, placebo-controlled data are available that support the role of immunosuppression to treat RA-associated ILD, despite being widely used in clinical practice. RESEARCH QUESTION: How does immunosuppression impact pulmonary function trajectory in a multisite retrospective cohort of patients with RA-associated ILD? STUDY DESIGN AND METHODS: Patients with RA who started treatment for ILD with mycophenolate, azathioprine, or rituximab were identified retrospectively from five ILD centers. Change in lung function before and after treatment was analyzed using a linear spline mixed-effect model with random intercept. Prespecified secondary analyses examined the impact of radiologic pattern of ILD (ie, usual interstitial pneumonia [UIP] vs non-UIP) on treatment trajectory. RESULTS: Two hundred twelve patients were included in the analysis: 92 patients (43.4%) were treated with azathioprine, 77 patients (36.3%) were treated with mycophenolate mofetil, and 43 patients (20.3%) were treated with rituximab. In the combined analysis of all three agents, an improvement in FVC % predicted was found after 12 months of treatment compared with the potential 12-month response without treatment (+3.90%; P ≤ .001; 95% CI, 1.95-5.84). Diffusing capacity of the lungs for carbon monoxide (Dlco) % predicted also improved at 12 months (+4.53%; P ≤ .001; 95% CI, 2.12-6.94). Neither the UIP pattern of ILD nor choice of immunosuppressive agent significantly impacted the pulmonary function trajectory on immunosuppression. INTERPRETATION: Immunosuppression was associated with an improved trajectory in FVC and Dlco compared with the pretreatment pulmonary function trajectory. Prospective, randomized trials are required to validate these findings.
引用
- Matson SM, Baqir M, Moua T, et al. Treatment Outcomes for Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Real-World, Multisite Study of the Impact of Immunosuppression on Pulmonary Function Trajectory. Chest. 2022. PMID: 36470416. doi:10.1016/j.chest.2022.11.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。